{{Rsnum
|rsid=10185316
|Gene=INSIG2
|Chromosome=2
|position=118086902
|Orientation=plus
|GMAF=0.2612
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=INSIG2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 43.4 | 46.0 | 10.6
| HCB | 73.7 | 24.1 | 2.2
| JPT | 80.5 | 18.6 | 0.9
| YRI | 53.7 | 36.1 | 10.2
| ASW | 43.9 | 45.6 | 10.5
| CHB | 73.7 | 24.1 | 2.2
| CHD | 76.1 | 20.2 | 3.7
| GIH | 45.5 | 44.6 | 9.9
| LWK | 57.3 | 34.5 | 8.2
| MEX | 70.7 | 24.1 | 5.2
| MKK | 55.5 | 39.4 | 5.2
| TSI | 54.9 | 34.3 | 10.8
| HapMapRevision=28
}}{{PMID Auto
|PMID=20045156
|Title=Common INSIG2 polymorphisms are associated with age-related changes in body size and high-density lipoprotein cholesterol from young adulthood to middle age
|OA=1
}}

{{PMID|20877301}} Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics.

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}